#BDTX hashtag - Bluesky

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM Black Diamond Therapeutics (NASDAQ: BDTX) reported preliminary Phase 2 results for silevertinib in frontline (1L) NSCLC and announced plans for a randomized Phase 2 trial in newly diagnosed GBM.Key 1L NSCLC data (n=43, data cutoff Nov 3, 2025): ORR 60%, CNS ORR 86%, DCR 91%; median follow-up 7.2 months; 29 patients remain on therapy. No new safety signals observed. PFS and DOR readouts expected Q2 2026.GBM plan: randomized ~150-patient Phase 2 starting 1H 2026 (silevertinib + TMZ vs TMZ), primary endpoint PFS; preliminary GBM data expected 2028. Cash $135.5M as of Sept 30, 2025, expected to fund operations into 2H 2028.

4 months ago

#BDTX Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

www.stocktitan.net/news/BDTX/black-diamond-...

0 0 0 0

@henrik.streetwi.se.ap.brid.gy

4 months ago

#BDTX Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BDTX/black-diamond-...

0 0 0 0

Henrik Ekenberg

6 months ago

BDTX

Same pattern.
Do you agree ?

( OverWi.se analyse : https://overwi.se/2025/09/15/bdtx-15-sep-2025/ )

#BDTX

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Most Searched, Wednesday September 10, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Sept 10th - #QUBT #RR #IQ #AEHL #BTBT #ASST #BBAI #ONDS #VMEO #WULF #DNN #VNET #UUUU #STSS #OCTO #ESPR #ENVX #BDTX #AEO #AAOI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Black Diamond Therapeutics (NASDAQ:BDTX) has reported its Q2 2025 financial results and provided significant updates on its clinical programs. The company has completed enrollment (n=43) in the Phase 2 trial of silevertinib for frontline non-classical EGFRm NSCLC patients, with ORR and preliminary DOR data expected in Q4 2025.The company ended Q2 2025 with $142.8 million in cash and investments, up from $98.6 million at the end of 2024, providing runway into Q4 2027. Net loss improved to $10.6 million compared to $19.9 million in Q2 2024, with reduced R&D expenses of $9.3 million and G&A expenses of $4.1 million.Black Diamond is actively exploring partnership opportunities for silevertinib's pivotal development in NSCLC and GBM, and plans to meet with the FDA in 1H 2026 regarding the 1L NSCLC development path when PFS data becomes available.

7 months ago

#BDTX Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BDTX/black-diamond-...

0 0 0 0

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Black Diamond Therapeutics (NASDAQ: BDTX) reported Q1 2025 financial results and corporate updates. The company ended Q1 with $152.4 million in cash and investments, marking strong financial position expected to fund operations into Q4 2027. Key highlights include anticipated Phase 2 clinical data for BDTX-1535 in Q4 2025 for non-classical EGFRm NSCLC patients, and expansion of a Phase 0/1 trial into newly diagnosed glioblastoma patients. The company secured a significant global licensing agreement with Servier for BDTX-4933, receiving a $70 million upfront payment and potential for up to $710 million in milestone payments plus tiered royalties. Q1 2025 showed a net income of $56.5 million, compared to an $18.2 million loss in Q1 2024, with reduced R&D expenses at $10.5 million and G&A expenses at $5.0 million.

10 months ago

#BDTX Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BDTX/black-diamond-...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #BDTX ) This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement

0 0 0 0

1 year ago

Breaking News: ( NASDAQ: #BDTX ) Black Diamond Therapeutics Inc. (NASDAQ: BDTX) Sees Notable Increase in Wednesday Morning Market Activity

0 0 0 0

1 year ago

Just In: ( NASDAQ: #BDTX ) Black Diamond Forges Global Pact with Servier for BDTX-4933, a Next-Gen Cancer Fighter

0 0 0 0

1 year ago

News; ( NASDAQ: #BDTX ) Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

0 0 0 0

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy Servier and Black Diamond Therapeutics (BDTX) have entered into a global licensing agreement for BDTX-4933, a Phase 1 targeted oncology therapy. The deal includes a $70 million upfront payment to Black Diamond, with potential additional payments of up to $710 million in development and commercial milestones, plus tiered royalties.BDTX-4933 is designed as a potential best-in-class treatment targeting both RAS mutations and RAF alterations in solid tumors, including non-small cell lung cancer (NSCLC). The drug is currently in Phase 1 development, evaluating safety, tolerability, and antitumor activity in patients with recurrent advanced/metastatic cancers harboring BRAF, CRAF, or NRAS mutations.Under the agreement, Servier will lead global development activities and commercialization of BDTX-4933 across multiple indications.

1 year ago

#BDTX Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

www.stocktitan.net/news/BDTX/servier-and-bl...

0 0 0 0

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Black Diamond Therapeutics (BDTX) has reported its Q4 and full year 2024 financial results. The company ended 2024 with $98.6 million in cash and equivalents, projected to fund operations into Q4 2026. Net loss for Q4 2024 was $16.0 million, improved from $19.4 million in Q4 2023.Key developments include anticipated Phase 2 clinical data for BDTX-1535 in Q2 2025 for first-line non-classical EGFRm NSCLC patients. The company plans to expand its 'window of opportunity' trial into newly diagnosed glioblastoma patients with EGFR aberrations in Q1 2025.Financial metrics show R&D expenses decreased to $51.3 million in 2024 from $59.4 million in 2023, while G&A expenses slightly increased to $27.5 million from $27.1 million. Full-year net loss improved to $69.7 million compared to $82.4 million in 2023.

1 year ago

#BDTX Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BDTX/black-diamond-...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish crossover of moving average convergence divergence signal, Mon Feb 10th - #XPEL #WPRT #UFPT #TBPH #SEVN #RZLT #PCRX #OCCI #MERC #JRVR #HRTX #ELTX #DCTH #CCSI #BDTX #UNFI #SMWB #GGT #DHT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0